TAIPEI, May 6, 2024 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, is pleased to announce the appointment of Dr. Steve Yang as its Chief Operating Officer (COO), effective on May 6th 2024. In this role, Dr. Yang will lead the company’s operational strategies, driving product development and innovation to foster REGiMMUNE’s growth across all aspect.

With over 20 years of extensive experience in the biotech industry, Dr. Yang brings a wealth of knowledge and leadership to REGiMMUNE. Prior to joining REGiMMUNE, he has founded a CRO to provide comprehensive clinical research services to several big pharmas. He has also joined Industrial Technology Research Institute (ITRI) to conduct project management and business development for various biomedical products. His proven track record of success in research and business development, aligns seamlessly with REGiMMUNE’s goals. REGiMMUNE also would like to leverage Dr. Yang’s business exposure as a senior executive in the TSE-listed company to accelerate the process of entering the capital market in Taiwan.

“We are thrilled to welcome Steve Yang to the REGiMMUNE team,” said Kenzo Kosuda, the chairman and the CEO of REGiMMUNE. “With his exceptional leadership skill and industry expertise, he will play a pivotal role in driving our company forward as we continue to expand global market through Taiwan-Japan collaboration. We are confident that he will make significant contributions to our growth and success.”

Dr. Yang expressed enthusiasm about his new role in REGiMMUNE, stating, “I’m extremely grateful to join this great company with distinctive pipeline and ambitious management team! REGiMMUNE signifies the deepening collaborative relationship between Japan and Taiwan. I strongly believe that this formula of success will bring fruitful progress to the medical profession and patients, and deliver value to all of our stakeholders in the shortest time!”

Steve Yang holds a PhD degree in Healthcare Organization and Research from Medical College of Virginia. He will be based at REGiMMUNE’s headquarters in Taipei, Taiwan, and will report directly to the CEO.

Ends

 

About REGiMMUNE Limited

REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.

Corporate Contact

Miranda Yu
Investor Relations Manager
REGiMMUNE Corporation Ltd.
+886 2 2555 3377 #511
miranday@regimmune.com

 

 

REGiMMUNE歡迎楊思聖博士擔任集團營運長

2024年5月6日，台北 – 瑞格國際生技，一家致力於開發免疫性疾病和癌症新型療法的臨床階段生技公司，很高興宣佈任命楊思聖博士擔任集團營運長 (COO) ，任期自2024年5月6日起生效。在這一職位上，楊博士將領導公司的營運策略，推動產品開發和創新，以促進瑞格在各方面的成長。

楊博士在生醫產業擁有超過20年的豐富經驗。在加入瑞格之前，他創辦了一家臨床研究服務公司，為多家大型藥廠提供臨床研究服務；他還加入了工業技術研究院 (ITRI)，參與多種生醫產品的研發管理和商業開發。他在研究和業務發展方面的成功經驗與瑞格的目標吻合，瑞格也希望透過楊博士曾經擔任上市公司高階管理員的商業背景加快進入台灣資本市場的過程。

「我們歡迎楊思聖加入瑞格團隊。」瑞格的董事長兼執行長小須田建三表示：「憑藉其卓越的領導能力和生醫領域專業知識，他將在推動我們公司向前發展方面發揮關鍵作用，持續通過台日合作擴大全球市場。我們相信他將對我們的增長和成功做出重大貢獻。」

楊博士對於在瑞格的新角色表達了期待，他表示：「我感到非常榮幸能夠加入擁有獨特新藥產品線的瑞格，我將與公司的新藥研發及管理團隊共同努力，在免疫及腫瘤領域持續提出安全有效的創新藥物。瑞格標誌著日本及台灣在生技醫藥產業的深化合作關係，我深信瑞格醫藥所構築的成功方程式，能為公司股東、臨床醫學界及病患，在最短時間內產出豐碩的果實！」

楊思聖博士擁有美國維吉尼亞醫學院的醫療管理博士學位。他將在瑞格在台北的總部工作，並直接向執行長匯報。

本文結束

 

關於瑞格國際生技

瑞格係為專注於自體免疫疾病與癌症，運用調控調節性T細胞(Tregs)，開發創新免疫療法之臨床生技公司。瑞格構建之全新候選藥物組合係藉由調控調節性T細胞活性，用於治療免疫疾病及癌症。

媒體聯絡人

余明穎 (Miranda Yu)
投資人關係經理
瑞格國際生技股份有限公司
+886 2 2555 3377 #511
miranday@regimmune.com